Tenaya reports Q1 net loss $31.7M; cash $173.6M; TN-201 gets FDA Fast Track

Tenaya Therapeutics, Inc.

2023-Q1 EPS reported -$0.43

Cash, equivalents and marketable securities $173.6M as of March 31, 2023; runway into H1 2025.
Net loss $31.7M ($0.43/share); R&D expense $25.6M, G&A $8.1M for Q1 2023.
TN-201 (gene therapy for HCM) received FDA Fast Track designation; Phase 1b to start Q3 2023.
Phase 1 dosing of TN-301 (HDAC6 inhibitor for HFpEF) complete; data expected H2 2023.
New Scientific Advisory Board members (Drs. Seidman, Marson) and Technical Advisory Board formed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tenaya Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 10, 2023, Tenaya Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020588

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.